Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 118122859 | 11812285 | 9 | F | 20151204 | 20160902 | 20151208 | 20160907 | EXP | US-GLAXOSMITHKLINE-US2015GSK174465 | GLAXOSMITHKLINE | 41.09 | YR | F | Y | 0.00000 | 20160907 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 118122859 | 11812285 | 1 | PS | FLOLAN | EPOPROSTENOL SODIUM | 1 | Intravenous (not otherwise specified) | 9 NG/KG/MIN, CO | U | V926 | 20444 | 9 | DF | POWDER FOR INFUSION | |||||
| 118122859 | 11812285 | 2 | SS | FLOLAN | EPOPROSTENOL SODIUM | 1 | Intravenous (not otherwise specified) | 9 NG/KG/MIN, CO | U | V785 | 20444 | 9 | DF | POWDER FOR INFUSION | |||||
| 118122859 | 11812285 | 3 | SS | FLOLAN | EPOPROSTENOL SODIUM | 1 | Intravenous (not otherwise specified) | 9 NG/KG/MIN CONTINUOUS; CONCENTRATION: 15,000 NG/ML; PUMP RATE: 54 ML/DAY; VIAL STRENGTH: 1.5 MG, CO | U | W674 | 20444 | POWDER FOR INFUSION | |||||||
| 118122859 | 11812285 | 4 | SS | FLOLAN | EPOPROSTENOL SODIUM | 1 | Intravenous (not otherwise specified) | 9 NG/KG/MIN, CO | U | Z111 | 20444 | 9 | DF | POWDER FOR INFUSION | |||||
| 118122859 | 11812285 | 5 | SS | FLOLAN | EPOPROSTENOL SODIUM | 1 | 9 NG/KG/MIN (CONCENTRATION 15,000 NG/ML, PUMP RATE 54 ML/DAY, VIAL STRENGTH 1.5 MG), CO | U | Z606 | 20444 | POWDER FOR INFUSION | ||||||||
| 118122859 | 11812285 | 6 | SS | FLOLAN | EPOPROSTENOL SODIUM | 1 | Intravenous (not otherwise specified) | 22 NG/KG/MIN (CONCENTRATION 45,000 NG/ML, PUMP RATE 64 ML/DAY, VIAL STRENGTH 1.5 MG), CO | U | Z880 | 20444 | 22 | DF | POWDER FOR INFUSION | |||||
| 118122859 | 11812285 | 7 | SS | FLOLAN | EPOPROSTENOL SODIUM | 1 | U | C769109 | 0 | SOLUTION FOR INJECTION | |||||||||
| 118122859 | 11812285 | 8 | C | SILDENAFIL CITRATE. | SILDENAFIL CITRATE | 1 | U | 0 | |||||||||||
| 118122859 | 11812285 | 9 | C | REVATIO | SILDENAFIL CITRATE | 1 | U | 0 | |||||||||||
| 118122859 | 11812285 | 10 | C | SILDENAFIL. | SILDENAFIL | 1 | U | 0 | |||||||||||
| 118122859 | 11812285 | 11 | C | NIFEDIPINE. | NIFEDIPINE | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 118122859 | 11812285 | 1 | Pulmonary hypertension |
| 118122859 | 11812285 | 7 | Pulmonary hypertension |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 118122859 | 11812285 | OT |
| 118122859 | 11812285 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 118122859 | 11812285 | Abdominal pain upper | |
| 118122859 | 11812285 | Emergency care examination | |
| 118122859 | 11812285 | Facial pain | |
| 118122859 | 11812285 | Hospitalisation | |
| 118122859 | 11812285 | Infection | |
| 118122859 | 11812285 | Influenza | |
| 118122859 | 11812285 | Intestinal stenosis | |
| 118122859 | 11812285 | Localised infection | |
| 118122859 | 11812285 | Oesophagitis | |
| 118122859 | 11812285 | Pneumonia | |
| 118122859 | 11812285 | Sepsis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 118122859 | 11812285 | 1 | 20100625 | 0 | ||
| 118122859 | 11812285 | 2 | 20100625 | 0 | ||
| 118122859 | 11812285 | 3 | 20100625 | 0 |